Close Menu

NEW YORK (GenomeWeb) – Protagen said today it is collaborating with Germany's National Center for Tumor Diseases (NCT) and NEC Laboratories Europe to improve approaches for in silico prediction of immunotherapy response in patients with malignant melanoma.

Under the collaboration, the parties will use machine learning approaches to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.